Aim-To develop a rapid, simple and highly specific DNA screening procedure based on the amplification refractory mutation system (ARMS) to detect the Leiden mutation in whole blood. Methods-ARMS PCR amplification primers with additional mismatches at either -2 or -3, which greatly improves specificity, were constructed to detect the normal Factor V gene and the Leiden mutation in whole blood samples from patients with abnormal clotting results. Results-Construction of ARMS primers with either an additional mismatch at -2 or -3 at the 3' end of the primer could be used to detect the Leiden mutation in 0.5 pl whole blood in under three hours. Primers destabilised at position -3 could be used at a lower annealing temperature, which gave greater sensitivity and are now routinely used. A control set of primers was included in the same reaction to act as a positive control. Conclusions-This rapid and specific assay for the factor V Leiden mutation is a useful addition to the investigation of patients with or at risk from thrombovascular disease.
Resistance to activated protein C (APCR) is the most common defect associated with an inherited predisposition to venous thrombosis.' About 95% of subjects with APC resistance have a mutation in the Factor V gene which results in a G to A substitution at nucleotide 1691, referred to as the Leiden mutation.2 In Europeans, this mutation has a frequency of 4.4%, but has been found in up to 50% of selected patients with a personal or family history of thrombosis. 3 Furthermore, it has been suggested that carriers of this mutation are at a sevenfold increased risk of developing thrombosis and this risk is increased to 30-fold in female carriers on oral contraceptives.4 Activated protein C resistance can be detected by a variety of coagulation based tests, but the Factor V Leiden abnormality can only be detected by direct analysis of the mutation.
We have developed a rapid, simple and highly specific DNA screening procedure based on the amplification refractory mutation system (ARMS) method,5 which uses whole blood samples directly in the assay. Normally, the ARMS method relies on the presence of a mismatch between the PCR oligonucleotide primer used and the target sequence such that the mismatch is at the 3' end (at position -1). In these circumstances the enzyme Taq polymerase functions inefficiently and a PCR product is not generated. This permits a rapid diagnosis directly from two PCRs on each sample.
Methods
Over 300 patients attending the anticoagulant clinic were typed by amplification of target DNA by PCR and restriction enzyme digest with MnlIV; 100 of these samples were used in the present study ARMS PROTOCOL Standard 50 gl PCR reactions (10 mM Tris-HCl, 2.5 mM MgCl2, 50 mM KC1, pH 8.3, 0.2 mM each dNTP) were used with 0.5-1.0 gl whole blood without the need to extract the DNA. We also found it necessary to increase the final MgCl2 concentration to 2.5 mM when using whole blood with sodium citrate anticoagulant. PCR tubes were heated to 95°C for five minutes and the temperature maintained. Diluted Taq polymerase (5 gl) (3.5 U) was added. Conditions for PCR were as follows: 58°C for 30 seconds (annealing), 72°C for 30 seconds (extension) and 95°C for 30 seconds (denaturing) for 32 cycles on a Biometra thermal cycler for the -3 ARMS primers. The annealing temperature was increased to 60°C for the -2 primers only. PCR products were visualised on a 2% agarose minigel and did not require any further manipulations for a diagnosis to be made. To improve the specificity of the reaction we deliberately introduced additional mismatches at position -2 or -3 with either a pyrimidine to pyrimidine (T to C) or pyrimidine to purine (T to G) substitution in the -2 primers and a pyrimidine to purine (C to A) substitution in the -3 primers. This destabilised the ARMS primers further and improved the specificity of detecting the Leiden mutation directly from whole blood samples.
By carrying out two PCR reactions for each sample, one tube with a normal ARMS amplification primer (tube A) and the other with the mutant ARMS primer (tube B), the presence or absence of a PCR product from each tube should permit an accurate diagnosis. An internal pair of control primers was included in the PCR to detect failed amplifications (table 1) . Scobie aDestabilised at position -2 with a T to C substitution. bDestabilised at position -2 with a T to G substitution. cDestabilised at position -3 with a C to A substitution.
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PCRs were set up as for the ARMS PCRs except that the annealing temperature was 61°C and the following primers were used: 5-CA AGTCTTAlTT1-CAAAGTACCAAG and 5-TA AAGCAATAGAGAAATGTCTGTA.
A 14 gl aliquot of the PCR product was removed and digested with MnlI for two hours at 370C . Digested products were analysed on a 12% acrylamide gel Results Figure 1 shows the detection pattern obtained with the ARMS procedure on whole blood samples. We have validated this procedure against the conventional use of PCR by digesting 100 whole blood samples with the MnlI restriction enzyme and have found the results to be totally consistent. Diagnosis could be readily achieved using either of the ARMS primers which were destabilised at positions -2 or -3. However, with the ARMS primers destabilised at position -2, we found a pyrimidine to pyrimidine substitution (T to C) was slightly more destabilising than a pyrimidine to purine (T to G) one, in that faint PCR products caused by the mutant ARMS primer annealing to normal sequence were observed very rarely. The ARMS primers with the T to C mismatch gave virtually identical results as the -3 mismatched primers but at a higher temperature (60°C). Annealing temperatures were slightly different for each pair of primers tested: the -2 primers worked best at 600C whereas the -3 were optimal at 58°C. Several pairs of internal primers were tried to avoid any spurious bands/primer dimers which could affect signal intensity. We now routinely use the ARMS primers with the additional C to A mismatch at position -3 for screening whole blood samples, and incorporate exon 4 primers of the cystic fibrosis gene in the PCRs as a control. We suggest, therefore, that this rapid and specific assay for the Factor V Leiden mutation is a useful addition to the investigation of individuals with or at risk from thrombovascular disease.
